切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2009, Vol. 03 ›› Issue (03) : 309 -316. doi: 10.3877/cma.j.issn.1674-0807.2009.03.008

临床研究

乳腺癌趋化因子受体CXCR4的表达及其意义
许建华1, 叶凯1, 郑正荣1, 许双塔1, 吴春霖2, 曾冰薇2   
  1. 1.362000福建 泉州,福建医科大学附属第二医院肿瘤外科
    2.362000福建 泉州,福建医科大学附属第二医院病理科
  • 收稿日期:2008-07-04 出版日期:2009-06-11
  • 基金资助:
    福建省科技三项费用资助项目(2006F5037)

CXCR4 expression in breast cancer and its significance

Jian-hua XU1, Kai YE1, Zheng-rong ZHENG1, Shuang-ta XU1, Chun-lin WU1, Bing-wei ZENG1   

  1. 1.Department of Oncology,Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China
  • Received:2008-07-04 Published:2009-06-11
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

许建华, 叶凯, 郑正荣, 许双塔, 吴春霖, 曾冰薇. 乳腺癌趋化因子受体CXCR4的表达及其意义[J/OL]. 中华乳腺病杂志(电子版), 2009, 03(03): 309-316.

Jian-hua XU, Kai YE, Zheng-rong ZHENG, Shuang-ta XU, Chun-lin WU, Bing-wei ZENG. CXCR4 expression in breast cancer and its significance[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2009, 03(03): 309-316.

目的

研究趋化性细胞因子受体CXCR4在乳腺癌中的表达,探讨其与淋巴结转移、远处转移及预后的关系。

方法

84例正常乳腺组织及84例乳腺癌组织、43例区域淋巴结转移癌组织标本(依据组织类型及临床病理特性分组),取自福建医科大学附属第二医院2000年1月至2002年12月手术切除的病理存档蜡块,应用免疫组化方法(二步法)分别检测3组标本CXCR4的表达情况。对计数资料采用χ2 检验,对生存率采用时序检验进行统计学分析。

结果

正常乳腺组织、乳腺癌组织、区域淋巴结转移癌组织CXCR4阳性率分别为11.9%、53.6%、74.4%;转移组织CXCR4阳性表达率明显高于原发肿瘤。乳腺癌组织CXCR4阳性表达率与淋巴结转移、HER-2表达、临床分期密切相关(P＜0.05), 而与患者年龄、肿瘤直径、ER表达、PR表达、组织学类型及肿瘤分化程度无关(P＞0.05)。发生远处转移组CXCR4表达水平(74.1%)高于未发生远处转移组(43.9%,P＜0.01)。CXCR4阳性表达组5年生存率66.7%(30/45)明显低于阴性表达组87.2%(34/39,P＜0.05)。

结论

CXCR4阳性表达与乳腺癌的淋巴结转移、远处转移有关,有助于预后判断。

关键词: 乳腺肿瘤, 趋化因子受体, 肿瘤转移, 预后

Objective

To investigate the expression of chemokine receptor CXCR4 in breast cancer and its correlation with lymphatic and distant metastasis and prognosis.

Methods

Samples of 84 cases of normal breast tissues,84 cases of breast cancer tissues and 43 cases of regional lymph node metastasis were obtained from the Second Affiliated Hospital of Fujian Medical University from January,2000 to December,2002.The expression of chemokine receptor CXCR4 in these samples was detected with immunohistochemistry.The results were processed with Chi-square test for paired numeration data and log-rank test for survival rate.

Results

The positive rates of CXCR4 expression in normal breast tissues,breast cancer tissues and regional lymph node metastasis were 11.9%,53.6%and 74.4%,respectively.Positive expression of CXCR4 was correlated with lymph node metastasis,clinical staging and HER-2 status (P＜0.05),but not with the age of patients,tumor size,ER,PR status and differentiation.The level of CXCR4 expression in the distant metastasis group(74.1%)was far higher than that in the non-metastasis group(43.9%).The 5-year survival rate in the group with positive expression of CXCR4(66.7%)was lower than that in the group with negative expression of CXCR4(87.2%,P＜0.05).

Conclusion

Positive expression of CXCR4 in breast cancer is significantly associated with lymphatic metastasis and distant metastasis,so can be used as a potential predictive factor for prognosis of breast cancer.

Key words: Breast neoplasms; CXCR4; Neoplasm metastasis; Prognosis
图1 CXCR4在乳腺癌组织中呈阴性表达(S-P染色×100)
图2 CXCR4在乳腺癌组织中呈阳性表达(S-P染色×100)
表1 乳腺癌CXCR4与临床病理因素之间的关系
临床病理因素 例数 阳性例数 阴性例数 χ2值 P值
年龄 0.09 0.76
＜50岁 51 28 23
＞50岁 33 17 16
肿瘤大小 0.04 0.85
＜2cm 28 15 13
2～5cm 44 23 21
＞5cm 12 7 5
肿瘤分化程度 0.40 0.52
高分化 38 19 19
中分化 29 16 13
低分化 17 10 7
组织学类型 1.30 0.26
浸润性导管癌 65 37 28
其他 19 8 11
ER 0.36 0.55
阳性 46 26 20
阴性 38 19 19
PR 1.13 0.29
阳性 44 26 18
阴性 40 19 21
HER-2 5.06 0.02
阳性 30 21 9
阴性 54 24 30
淋巴结转移 5.46 0.02
有 48 31 17
无 36 14 22
远处转移 6.72 0.01
有 27 20 7
无 57 25 32
分期 4.86 0.03
Ⅰ+Ⅱ期 59 27 32
Ⅲ期 25 18 7
图3 乳腺癌组织CXCR4表达水平与生存率的关系 P=0.028,CXCR4阳性组与阴性组比较
[1]
Spano J P,Andre F,Morat L,et al.Chemokine receptor CXCR4 and early-stage non-small cell lung cancer:pattern of expression and correlation with outcome.Ann Oncol,2004,15:613-617.
[2]
Koshiba T,Hosotani R,Miyamoto Y,et al.Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer:a possible role for tumor progression.Clin Cancer Res,2000,6:3530-3535.
[3]
Kang H,Watkins G,Douglas Jones A,e t al.The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer.Breast,2005,14:360-367.
[4]
许良中,杨文涛.免疫组织化学反应结果的判断标准.中国癌症杂志,1996,6:229-231.
[5]
Muller A,Homey B,Soto H,et al.Involvement of chemokine receptors in breast cancer metastasis.Nature,2001,410:50-56.
[6]
Salvucci O,Bouchard A,Baccarelli A,et al.The role of CXCR4 receptor expression in breast cancer:a large tissue microarray study.Breast Cancer Res Treat,2005,13:1291.
[7]
李文仿,王耕,王明华.乳腺癌患者CXCR4的表达及其与组织学分级和淋巴结转移的关系.中国全科医学,2008,11:833-835.
[8]
Kato M,Kitayama J,Kazama S,et al.Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma.Breast Cancer Res,2003,5:R144-R150.
[9]
丁勇兴,李成华,杨清玲,等.CXCR4 表达水平对判断乳腺癌淋巴结转移潜能的意义.中国肿瘤临床,2008,35:88-91.
[10]
Katayama A,Ogino T,Bandoh N,et al.Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma.Clin Cancer Res,2005,11:2937-2946.
[11]
Liang Z,Yoon Y,Votaw J,et al.Silencing of CXCR4 blocks breast cancer metastasis.Cancer Res,2005,65:9672-9711.
[12]
Li Y M,Pan Y,Wei Y,et al.Up-regulation of CXCR4 is essential for HER-2 mediated tumor metastasis.Cancer Cell,2004,6:459-469.
[13]
Cabioglu N,Sahin A,Doucet M,et al.Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.Clin Exp Metastasis,2005,22:39-46.
[14]
Schimanski C C,Schwald S,Simiantonaki N,e t al.Effect of chemikine receptors CXCR4 and CCR7 on the metastatic behaviour of human colorectal cancer.Clin Cancer Res,2005,11:1743-1750.
[15]
Kim J,Takeuchi H,Lam S T,et al.Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.Clin Oncol,2005,23:2744-2753.
[16]
Tamamura H,Hori A,Kanzaki N,et al.T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.FEBS Lett,2003,550:79-83.
[17]
Zeelenberg I S,Ruuls Van Stalle L,Roos E.The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases.Cancer Res,2003,63:3833-3839.
[18]
厉红元,任国胜,谭金详.siRNA 沉默人乳腺癌细胞株CXCR4 基因的实验研究.第三军医大学学报,2007,29:728-730.
[19]
王欣,闫哲,李晓青,等.Cystain M 在乳腺癌及转移癌中的表达和临床意义.中华乳腺病杂志:电子版,2008,2:294-300.
[1] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[6] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[7] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[8] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[9] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[10] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[11] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[12] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[13] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[14] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号